Sciences de la vie - réglementation

eAlerts Récentes

•  

  23.11.2023

  United Kingdom

  Autumn Statement 2023 – Key tax announcements

  The Chancellor opened his speech with a statement that, “Our plan for the British economy is working, but the work is not done”.  Consistent, perhaps, with the tone of that message, yesterday’s announcements offered few real surprises, with the headline measures – on NI changes and full expensing – already widely anticipated.A summary of the key announcements follows.Tax measures for individuals (employees & self-employed)National Insurance Contributions (NICs) ratesIn relation to NICs, the Chancellor has announced the following.The main rate of Class 1 National...

  Lire la suite
•  

  22.11.2023

  United Kingdom

  DHSC and ABPI agree 2024 voluntary scheme for branded medicines pricing, access and growth (“VPAG”)

  The 2024 voluntary scheme for branded medicines pricing, access and growth (“VPAG”) provides for accelerated growth of the NHS’s annual branded medicines spend, introduces differentiated reimbursement levies for “newer” and “older” medicines, and establishes a new investment facility to fund the development of innovative treatments. On Monday 20 November, the Department of Health and Social Care (“DSHC”, representing the UK Government, the governments of Scotland and Wales and the Northern Ireland Department of Health), and the Association of...

  Lire la suite
•  

  09.11.2023

  Europe

  CMS Life Sciences Vital Signs, Winter 2023

  2023 has seen some significant legal developments impacting the life sciences industry, and as we look ahead to 2024, there are several important developments which we would like to keep our clients informed of.In the UK, beginning in January 2024, the UK will roll out a new International Recognition Procedure for medicines approved in trusted jurisdictions. There are also new public procurement rules on the horizon as the Procurement Bill has been progressing through the Houses of Parliament, with the aim to make the UK’s public procurement regime more efficient and transparent.In Europe,...

  Lire la suite
•  

  20.10.2023

  Ukraine

  Through new law Ukraine adopts telemedicine in the face of war

  On 4 September 2023, the President of Ukraine signed the Law of Ukraine On Amendments to Certain Legislative Acts of Ukraine on the Functioning of Telemedicine, which establishes a comprehensive and up-to-date approach on state policy in the field of telemedicine with a goal to improve the quality and accessibility of medical services, expand opportunities for patients, improve management and optimise the use of healthcare resources. This law was passed by parliament on 9 August 2023.The driving factors behind these amendments to Ukraine’s healthcare laws include the COVID-19 pandemic and...

  Lire la suite
•  

  12.10.2023

  United Kingdom

  Have your say on unregulated cosmetic procedures before 28 October 2023

  Introduction  On 2 September 2023, the UK government launched its first-ever consultation on non-surgical cosmetic procedures. Last year the Health and Care Act 2022 called for these treatments to become licensed. The consultation includes the proposal of a new traffic light licensing scheme and a minimum age of consent.Cosmetic (non-surgical) procedures cover a wide range of treatments including botulinum toxin injections (such as Botox), laser hair removal, chemical peels, tattoo removal, dermal fillers, skin lightening and permanent make-up. The majority of these treatments are ...

  Lire la suite
•  

  12.10.2023

  England and Wales

  A class apart – Court of Appeal considers class rights and automatic conversions of shares

  The Court of Appeal has recently given guidance on the interpretation of a company’s articles of association where the Court found a conflict between provisions dealing with the conversion of preferred shares to ordinary shares and the requirements for class consent.In a rare case, the Court of Appeal upheld the first instance judgment that, on their proper construction, there was an implied term in the articles – despite certain words being “clear and unambiguous” – that class consent was required to convert preferred shares to ordinary shares and that the purported...

  Lire la suite